Drug discovery utilizes chemical biology and computational drug design approaches for the
efficient identification and optimization of lead compounds. Chemical biology is mostly …

Recent research in drug discovery dealing with many faces difficulties, including
development of new drugs during disease outbreak and drug resistance due to rapidly …

Drug attrition late in preclinical or clinical development is a serious economic problem in the
field of drug discovery. These problems can be linked, in part, to the quality of the compound …

A common underlying assumption in current drug discovery strategies is that compounds
with higher in vitro potency at their target (s) have greater potential to translate into …

The modulation of PPIs by low molecular weight chemical compounds, particularly by orally
bioavailable molecules, would be very valuable in numerous disease indications. However …

During the research and development of new drugs directed at the central nervous system,
there is a considerable attrition rate caused by their hampered access to the brain by the …

The blood-brain barrier (BBB) is an active interface between the circulation and the central
nervous system (CNS) with a dual function: the barrier function restricts the transport from …

The blood–brain barrier (BBB) acts as a barrier to prevent the central nervous system (CNS)
from damage by substances that originate from the blood circulation. The BBB limits drug …

Spinal muscular atrophy (SMA), a rare neuromuscular disorder, is the leading genetic cause
of death in infants and toddlers. SMA is caused by the deletion or a loss of function mutation …

Brain drug delivery may be restricted by the blood-brain barrier (BBB), and enhancement by
liposome-based drug delivery strategies has been investigated. As access to the human …